PCM
Penserra Capital Management Portfolio holdings
AUM
$7.17B
1-Year Return
49.58%
This Quarter Return
+33.7%
1 Year Return
+49.58%
3 Year Return
+118.16%
5 Year Return
+229.83%
10 Year Return
–
AUM
$4.23B
AUM Growth
+$1.6B
(+61%)
Cap. Flow
+$935M
Cap. Flow
% of AUM
22.08%
Top 10 Holdings %
Top 10 Hldgs %
21.32%
Holding
1,174
New
230
Increased
606
Reduced
167
Closed
168
Top Buys
| 1 |
KE Holdings
BEKE
|
+$78.6M |
| 2 |
Lufax Holding
LU
|
+$56.6M |
| 3 |
Groupon
GRPN
|
+$50.3M |
| 4 |
JD.com
JD
|
+$43.7M |
| 5 |
Lands' End
LE
|
+$36.7M |
Top Sells
| 1 |
JMIA
Jumia Technologies
JMIA
|
+$35.9M |
| 2 |
Peloton Interactive
PTON
|
+$31.3M |
| 3 |
Match Group
MTCH
|
+$23.5M |
| 4 |
Fiverr
FVRR
|
+$16.6M |
| 5 |
Stitch Fix
SFIX
|
+$14.7M |
Sector Composition
| 1 | Consumer Discretionary | 35.59% |
| 2 | Technology | 23.48% |
| 3 | Communication Services | 13.86% |
| 4 | Real Estate | 4.37% |
| 5 | Industrials | 4.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
626
MSCI
MSCI
$44.5B
| $76K | ﹤0.01% |
172
+36
| +26% | +$15.9K |
|
627
Intellia Therapeutics
NTLA
$1.27B
| $74K | ﹤0.01% |
1,365
+861
| +171% | +$46.7K |
|
|
DCPH
628
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $74K | ﹤0.01% |
1,305
+823
| +171% | +$46.7K |
|
629
Alkermes
ALKS
$4.7B
| $73K | ﹤0.01% |
3,680
-2,346
| -39% | -$46.5K |
|
630
ALX Oncology
ALXO
$59.4M
| $73K | ﹤0.01% |
+850
| New | +$73K |
|
631
Bank of New York Mellon
BK
$73.4B
| $73K | ﹤0.01% |
1,726
+366
| +27% | +$15.5K |
|
632
CoStar Group
CSGP
$37.3B
| $73K | ﹤0.01% |
800
+460
| +135% | +$42K |
|
633
Johnson Controls International
JCI
$70.1B
| $73K | ﹤0.01% |
1,577
+319
| +25% | +$14.8K |
|
634
Parker-Hannifin
PH
$96.3B
| $73K | ﹤0.01% |
271
+67
| +33% | +$18K |
|
635
Roku
ROKU
$14.6B
| $73K | ﹤0.01% |
222
-432
| -66% | -$142K |
|
636
Trane Technologies
TT
$92.3B
| $73K | ﹤0.01% |
507
+133
| +36% | +$19.2K |
|
637
Centene
CNC
$14.2B
| $72K | ﹤0.01% |
1,206
+220
| +22% | +$13.1K |
|
638
IQVIA
IQV
$31.9B
| $71K | ﹤0.01% |
397
+91
| +30% | +$16.3K |
|
639
MetLife
MET
$52.9B
| $70K | ﹤0.01% |
1,493
+303
| +25% | +$14.2K |
|
640
Nektar Therapeutics
NKTR
$843M
| $70K | ﹤0.01% |
276
+174
| +171% | +$44.1K |
|
641
Verisk Analytics
VRSK
$38.1B
| $70K | ﹤0.01% |
342
+70
| +26% | +$14.3K |
|
642
Cummins
CMI
$54.8B
| $70K | ﹤0.01% |
309
+71
| +30% | +$16.1K |
|
643
Agios Pharmaceuticals
AGIO
$2.12B
| $69K | ﹤0.01% |
1,600
+1,010
| +171% | +$43.6K |
|
644
American International
AIG
$43.6B
| $69K | ﹤0.01% |
1,830
+402
| +28% | +$15.2K |
|
645
Axsome Therapeutics
AXSM
$6.45B
| $69K | ﹤0.01% |
855
+535
| +167% | +$43.2K |
|
646
Carrier Global
CARR
$55.8B
| $69K | ﹤0.01% |
1,842
+380
| +26% | +$14.2K |
|
647
O'Reilly Automotive
ORLY
$90.3B
| $69K | ﹤0.01% |
2,295
+255
| +13% | +$7.67K |
|
648
Rocket Pharmaceuticals
RCKT
$352M
| $69K | ﹤0.01% |
1,275
+803
| +170% | +$43.5K |
|
|
INFO
649
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $69K | ﹤0.01% |
776
-1,138
| -59% | -$101K |
|
|
NSTG
650
DELISTED
NanoString Technologies, Inc.
NSTG
| $67K | ﹤0.01% |
1,010
+686
| +212% | +$45.5K |
|